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Abstract
In randomized clinical trials, it is common that patients may stop taking their assigned treatments 
and then switch to a standard treatment (standard of care available to the patient) but not the 
treatments under investigation. While the availability of limited retrieved data on patients who 
switch to standard treatment, called off-protocol data, could be highly valuable in assessing the 
associated treatment effect with the experimental therapy, it leads to a complex data structure 
requiring the development of models that link the information of per-protocol data with the off-
protocol data. In this paper, we develop a novel Bayesian method to jointly model longitudinal 
treatment measurements under various dropout scenarios. Specifically, we propose a multivariate 
normal mixed-effects model for repeated measurements from the assigned treatments and the 
standard treatment, a multivariate logistic regression model for those stopping the assigned 
treatments, logistic regression models for those starting a standard treatment off protocol, and a 
conditional multivariate logistic regression model for completely withdrawing from the study. We 
assume that withdrawing from the study is non-ignorable but intermittent missingness is assumed 
to be at random. Various properties of the proposed model are examined. An efficient Markov 
chain Monte Carlo sampling algorithm is developed. A real data set from a clinical trial is 
analyzed in detail via the proposed method.
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In a drug development setting, research and debate on improving the handling of missing 
data in clinical trials has often focused on demonstrating the advantage of model-based 
approaches that aim to employ a clear set of assumptions, such as using a mixed model in a 
longitudinal analysis that implicitly assumes either missing at random assumption (MAR) or 
missing not at random (MNAR), over the more traditional approaches that are based on 
single data imputations, including last observation carried forward (LOCF) and baseline 
observation carried forward (BOCF) ([1, 2, 3, 4]). As the LOCF and BOCF have been 
applied in the primary analysis of the vast majority of confirmatory phase III trials, the 
arguments for those developments are well motivated. However, recent work by the 
National Research Council Panel on Handling Missing Data in Clinical Trials emphasizes 
the need to combine better methods for the prevention of missing data with well principled 
modeling strategies (Panel on Handling Missing Data in Clinical Trials and National 
Research Council [5]).
Here focus shall be placed on the third recommendation of the National Research Council 
that trial sponsors should continue to collect information on key outcomes on participants 
who discontinue their protocol-specified intervention in the course of the study. If 
improvements in data retrieval strategies are to be made, the likely consequence is a final 
analysis dataset consisting of patients with at least three types of follow-up: 1) patients with 
complete data; 2) patients who drop-out of the study at a certain time point and no further 
data is collected; 3) patients who drop-out but a certain amount of data is retrieved following 
withdrawal from study medication when it is ethical. Up until now, little thought has gone 
into appropriate statistical analysis for such “mixed data” structures.
The literature on missing data methods for longitudinal studies is enormous and far too 
numerous to list here. There have been many likelihood-based approaches as well as 
weighted estimating approaches proposed in the literature. Estimating parameters with 
nonignorable missing data is complex. Likelihood-based methods require specification of 
the joint distribution of the data and the missing data mechanism. This specification can be 
further classified into three types of models: selection, pattern-mixture, and shared-
parameter models [13]. The selection modeling approach models the hypothetical complete 
data together with the missing data process conditional on the hypothetical complete data. 
The pattern-mixture approach models the distribution of the data conditional on the missing 
data pattern. The third approach, shared-parameter models, accounts for the dependence 
between the measurement and missingness processes by means of latent variables such as 
random effects ([6, 7, 8, 9]). The literature on maximum likelihood estimation with 
nonignorable missing longitudinal data models includes [10] and [11]. The main emphasis is 
on continuous and normally distributed outcomes. A substantial part of the literature also 
assumes monotone patterns of missingness, where sequences of measurements on some 
subjects simply terminate prematurely. Approaches using selection models include [12, 13, 
14] among others. Approaches based on pattern-mixture models include [13, 15, 16, 17, 18]. 
A comprehensive review paper on missing data in longitudinal studies is given in [19] and 
contains many references. We mention here that although there has been a substantial 
literature for longitudinal data with nonignorable missing outcomes, there has been virtually 
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no literature at all for modeling and accommodating longitudinal “off-protocol data”, that is 
modeling the longitudinal process while patients are on the assigned treatment, and then also 
jointly modeling the longitudinal process when patients stop taking the assigned treatment, 
and then start taking a “standard treatment”, which is the term we shall use for the standard 
of care available to a patient once they stop taking the treatment assigned to them in the 
clinical trial. Related but different challenges can also be found in the literature of 
noncompliance, in which causual inference has been shown to be a useful inference tool 
([20, 21]). In the noncompliance studies, it is typically assumed that the patients would 
switch to the other treatment arm under investigation when noncompliant, however, this is 
not the situaton for our motivating study, in which the “standard-treatment” is different from 
the treatments under investigation. Modeling such “off-protocol data” poses many new 
statistical challenges not addressed in the literature. First, there is the issue of how to model 
the response and missingness mechanisms for the longitudinal component for those on the 
assigned treatment and those on the standard treatment. Second, there is the issue of defining 
an intent-to-treat analysis. Third, there is also the critical issue of model identifiability which 
needs to be addressed. In this paper, we address these issues and present a novel model for 
missing longitudinal data that accommodates a longitudinal structure for patients taking the 
assigned experimental treatment as well as patients taking a standard treatment after 
stopping the assigned treatment upon dropping out of the study.
The remainder of this paper is structured as follows. Section 2 introduces a motivating 
example based on a trial examining an experimental treatment for mild cognitive 
impairment (MCI). In Section 3 we develop a methodological framework that is later 
applied to the MCI trial in Section 5. Prior and posterior distributions are presented in 
Section 4, and in the same section, an efficient Gibbs sampling algorithm is developed. 
Finally, the ideas and limitations is discussed along with various possible extensions in 
Section 6.
2. The Mild Cognitive Impairment Study
To help exemplify and develop methods for the “mixed data structure” described in Section 
1, a Phase III randomized, multicenter, double-blind, placebo-controlled study is considered, 
that examined the effect of the experimental treatment Exelon on subjects with mild 
cognitive impairment (MCI). Although MCI can present with a variety of symptoms, when 
memory loss is the predominant symptom it is termed “amnestic MCI” and is frequently 
seen as a risk factor for Alzheimer’s disease [22]. At the time of the study, the experimental 
treatment Exelon was already approved for the treatment of Alzheimer’s disease (AD). 
Therefore, it was hypothesized that treatment of subjects with MCI might delay progression 
of amnestic MCI to AD due to the induction of symptomatic improvements. One of the co-
primary endpoints for this study is the change from baseline in the long-term effects of 
taking Exelon versus placebo on a cognitive function score made up of a battery of cognitive 
tests.
As described in the protocol, the enrolled patients had regular visits every six months until 
the 36th month, corresponding to visits 1 to 6. At each visit, the cognitive function score was 
measured and then transformed to a continuous composite z-score. In the trial, investigators 
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encouraged subjects who discontinued study treatment to continue coming to the clinic for 
regularly scheduled 6-month visits, until the planned end of the study. Therefore, to clarify 
the difference, we describe the score as a per-protocol outcome if it was measured when the 
patient was taking the assigned treatment, and as a off-protocol outcome if it was measured 
after the patient discontinued their assigned treatment and returned to standard of care. It is 
noted that other types of protocol violations could occur, here to simplify the presentation, 
we shall only focus on withdrawal from a randomized study treatment. The per- and off-
protocol schedule is complex in this study. To illustrate, we listed some selected per- and 
off-protocol patterns together with one of its associated outcome measurements in the top 
section of Figure 1. We called the patients “Return Patients” if they ever returned to the 
clinic after discontinuing the assigned treatment “Non-return Patients” if they never came 
back to the clinic after discontinuing the assigned treatment, and “Never-stopped Patients” if 
they never discontinue the assigned treatment. In the bottom section of Figure 1, we 
presented the boxplots of the per-protocol outcome measurements for “Return Patients” 
(top), “Non-return Patients” (top middle), and “Never-stopped Patients” (bottom middle), 
and the off-protocol outcome measurements for “Return Patients” (bottom) only. No 
clinically meaningful difference between the two treatments was observed from the graph.
Given the longitudinal follow-up, it is interesting to examine longitudinal models that 
incorporate information on subjects with retrieved data, to form more appropriate 
assumption about subjects who dropped out with no further retrieved data. In the following 
section, a general methodological framework is developed for this type of modeling.
3. Methodological Development
3.1. Notation
To accommodate the longitudinal process for patients on the assigned treatment, standard 
treatment, and study dropout, we need to define three random variables, R, S, and L, and 
hence develop a regression model for each variable. Let ri be the time point at which the ith 
patient stops taking the assigned treatment, and thus ri is a categorical response variable. 
The possible values of ri include 1,…, K, K + 1, where ri = K + 1 implies that the ith patient 
never switches the treatment and thus never drops out from the study. Let si be the time 
point at which ith patient starts the standard treatment. The possible values of si include 1,
…, K, K + 1 with the constraint that si ≥ ri, where si = K + 1 implies that the ith patient 
never starts the standard treatment. Let ℓi be the time point at which a patient completely 
withdraws from the study. As in the case of ℓi, the possible values of ℓi include 1,…, K, K + 
1, under the restriction that ℓi ≥ ri, and ℓi = K + 1 implies that the ith patient never drops out 
from the study. For example, for a patient with ri = si = 3 and ℓi = 5, he/she switched from 
assigned treatment to standard treatment between the second and third visits, and then 
dropped out and did not come to the fifth visit.
The variables ri, si and ℓi categorize the patients into four groups:
1. patients stick to the planned treatment for the whole study period (never-stopped 
patients): ri = si = ℓi = K + 1;
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2. patients discontinue the study treatment but still come back to the clinic for all 
scheduled visits until the end of study (return patients without dropout): ri ≤ si < K 
+ 1 and ℓi = K + 1;
3. patients discontinue the study treatment but still come back to the clinic for some 
scheduled visits (return patients with dropout): ri ≥ si < ℓi < K + 1; and
4. patients discontinue the study treatment and never come back to the clinic for 
regularly scheduled visits (never-returned patients): ri = ℓi < K + 1 and si = K + 1.
Due to the nature of clinical trials, the patients switching to the standard treatment will not 
resume their assigned treatments. The following two patterns hold in general regarding 
variables ri, si and ℓi: (i) if ri = K + 1, then si = ℓi = K + 1; (ii) if ri < K + 1 and si = K + 1, 
then ℓi = ri. Another pattern observed in the MCI study and required by our proposed 
approach, but may not hold in general is:
Assumption A.1: If ri < K + 1, then si = ri or si = K + 1.
We called this seamless assumption. It assumes that if the patients stop taking the assigned 
treatment, they will either start the standard treatment right away without missing the visit or 
drop out from the study completely. This assumption leads to another general pattern: (iii) if 
ri < K + 1 and si < K + 1, then si = ri and si + 1 ℓi ≥ K + 1. The proposed method is 
developed under the Assumption A.1 and the patterns (i) to (iii).
We let yik denote the observed continuous primary outcome, which is the outcome measured 
from the assigned treatment when k < ri and the outcome measured from the standard 
treatment when k ≥ ri. Let zi denote the binary treatment covariate at baseline, where Zi = 1 
indicates a patient is assigned to the experimental group and zi = 0 indicates a patient is 
assigned to control, and let xi be a column vector of other baseline covariates for the ith 
patient. We also let gik denote the missing indicator for outcome measurement such that gik 
= 1 if yik is missing and gik = 0 if yik is observed. When gik = 1 and k < ri, yik from the 
assigned treatment is intermittently missing. Similarly, when gik = 1 and si ≤ k < ℓi, yik from 
the standard treatment is intermittently missing. Furthermore, we make the following 
assumption for notation convenience.
Assumption A.2: If gik = 1 and ℓi ≤ k < si, the missing value yik is from the standard 
treatment.
In other words, we assume for those never-returned patients, if the outcome measurements 
after dropout were observed, they were measured from standard treatment.
3.2. The Model
We use [A|B] to denote the condition distribution of A given B. We will model the observed 
data through a sequence of conditional distribution functions [Ri] [Yi|Ri] [Si|Ri, Yi][Li|Ri, Yi, 
Si].
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We first model [Ri]. Since Ri, the time point at which the ith patient stops taking the 
assigned treatment, is a categorical response variable taking K + 1 distinct values, we 
propose a multivariate logistic regression model for Ri as follows:
(3.1)
A multivariate normal mixed effects model is proposed for the observed continuous 
outcome yik given ri. Because the treatment effects will be included in the both measurement 
types at the kth visit of time tk, the model must be structured in a way that allows synthesis 
of the treatment effects, in-turn producing an overall treatment effect. Taking these factors 
into consideration, the model for yi = (yi1, …, yiK) assumes:
(3.2)
where β1 and β2 are the vectors of regression coefficients corresponding to the baseline 
covariates xi and
(3.3)
Let εi1 = (εi11, …, εi1K)′ and εi2 = (εi21, …, εi2K)′ denote the vectors of error terms in (3.2). 
We assume εi1 and εi2 are independent,
(3.4)
where Σj = (σjkk′) is a K × K unstructured variance-covariance matrix for j = 1,2. We note 
that in (3.2), the subject level random effects υi, i = 1, …, n, are assumed to be common 
across the measurements from the assigned and standard treatments. Note that unlike the 
regular longitudinal study, τ, Σ1, and Σ2 are estimable since τ can be estimated from patients 
receiving both the assigned and standard treatments, while the patients with more than one 
visit when they are taking the assigned treatment and more than one visit when they are 
taking standard treatment are used to estimate Σ1 and Σ2, respectively. The inclusion of zi in 
the yik model when k ≥ ri could account for possible carry-over effects. Under the model in 
(3.2), given the subject random effect υi, the outcome measurements from the assigned 
treatment and standard treatment are assumed to be independent and, however, they are 
dependent across different visits when receiving the same treatment. Let γj = (γj01, …, γj0K, 
γj11, …, γj1K)′, , Σ = (Σ1, Σ2), and partition Σj as
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for j = 1, 2. Then, conditional on the subject level random effect υi and ri, the distribution of 
yi is given by
(3.5)
where 
, and Wi = diag(Σ1,1:ri − 1,1:ri − 1, Σ2,ri:K,ri:K). The conditional density of yi given ri is given 
by
(3.6)
Next, conditioning on Ri = ri and yi, we model the variable Si, which is the time-point at 
which the ith patient starts the standard treatment. This conditional model for Si given Ri = ri 
= assumes
(3.7)
where logit−1 (u) = exp(u)/(1 + exp(u)),  and λ2 is a 
vector of the regression coefficients of (xi, yi,ri − 1). We assume S that is MAR but may 
depend on the observed outcome.
Conditional on Ri = ri = and Si = si, we model the random variable Li, which is the time-
point a patient completely withdraws from the study, that is, the patient stops taking the 
assigned treatment as well as the standard treatment if any. Note that we need to model Li 
only when ri ≤ si < K. The subset of the data with ri ≤ si < K is often sparse, especially when 
K is small. Conditional on Ri = ri and Si = si, we propose a more parsimonious multivariate 
logistic regression model for Li, which is stated as follows:
(3.8)
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where t = (t1,…, tK)′, wi is a vector of covariates, which may be a subset of xi, and 
. This is a non-ignorable model as (3.8) depends on the off-protocol 
responses, (yisi, yi,si+1,…, yi,K−1)′, in which yili, yi,li+1, … yi,K−1 are not observed.
The proposed multivariate response model defined by (3.2)–(3.4) assumes a general 
covariance structure for the repeated measurements from the assigned standard treatment 
and the repeated measurements from the standard treatment over time. It captures the 
dependence between per- and off-protocol responses by random intercept υi, which may be 
extended to other random effect model to allow for more general dependency. Furthermore, 
the joint distribution of three types of missing data mechanisms in the longitudinal process 
(Ri, Si, Li) and the outcome Yi via (3.1) and (3.6)–(3.8) is modeled by a sequence of the 
conditional distributions via [Ri] [Yi|Ri] [Si|Yi, Ri][Li|Ri, Yi, Si]. These models are quite new, 
as modeling such data has not been attempted in the statistical literature.
3.3. The Likelihood Functions
Let ψ = (γ, β, θ, λ, α, τ, Σ1, Σ2) denote the collection of all model parameters. Write υ = (υ1,
…, υn)′. Denote the complete data by Dc = {yi, zi, xi, υi, wi, ri, si, ℓi, i = 1,…, n} and the 
observed data by Do = {(yik(1 − gik), k = 1, …, K), zi, xi, wi, ri, si, ℓi, i = 1, …, n}. Then, the 
complete data likelihood function is given by
(3.9)
where the density functions are defined in (3.5)–(3.8).
Let yi,mis = (yikgik, k = 1, …,K) denote the vector of missing per-protocol or off-protocol 
outcomes. The observed data likelihood function is written as follows:
(3.10)
We can leave fS|R(si|ri, zi, xi, yi,ri − 1, λ) outside the integration in (3.10). This is because 
yi,ri − 1 cannot be missing, otherwise, by definition the time point at which the ith patient 
stops taking the assigned treatment should take the value of ri − 1 but not ri.
4. Posterior Inference
4.1. Prior and Posterior
We specify independent priors for γ, β, θ, λ, α, τ, Σ1 and Σ2. Thus, the joint prior is given by
(4.1)
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Specifically, for each of γ, β, θ, λ and α, we take a noninformative multivariate normal prior 
N(0,1000I), where I is a generic notation denoting an identity matrix with the dimension 
matching each of these parameter vectors. Also, we take an Inverse-Wishart distribution, 
Inv-Wishartd0( ), for Σj for j = 1,2 with density π(Σj) ∝ |Σj|
−(d0 + K + 1)/2 
 for j = 1, 2, where the degrees of freedom d0 and the K × K positive 
definite matrix Σ0 are prespecified. We further assume an inverse gamma priors Inv-
Gamma(a, b) for τ2 with density . In Section 5, we took d0 = K 
+ 1, Σ0 = 0.001IK, and a = 2.001 and b = 0.01, which are fairly noninformative.
Write . Then, the joint posterior distribution of (ψ, v, ymis) given 
the observed data D0 takes the form:
(4.2)
where ℒc(ψ|Dc) is defined by (3.9). Using the results established in [23] and [24], we can 
show that under some mild conditions, the posterior π(ψ, v, ymis|Do) is proper when π(θ) ∝ 
1, π(λ) ∝ 1, and π(α) ∝ 1. Thus, the proposed models (3.1), (3.7), and (3.8) for R, S, and L 
are identifiable in this sense.
4.2. Posterior Computation
Due to the complexity of the random-effects regression models for repeated treatment 
outcomes and logistic regression models for ri, si, and ℓi, it does not appear possible to 
obtain an analytic evaluation of the posterior distributions. Also, due to a large percentage of 
missing values in both per- and off-protocol outcome measurements, there is a need to 
develop an efficient Markov chain Monte Carlo (MCMC) sampling algorithm to sample (ψ, 
υ, ymis) from the posterior distribution π(ψ, υ, ymiss|Do). In this regard, we use the modified 
collapsed Gibbs technique of Liu [25] as discussed in Chen et al. [26] to collapse out as 
many missing yi,mis as possible when we sample γ, β, υ, and Σ. Let yi,obs = (yik(1 − gik), = 1, 
…, K) denote the vector of observed treatment outcomes for 
. The Gibbs sampling 
algorithm requires to sample from the following conditional posterior distributions in turn: 
(i) [θ|Do]; (ii) [λ|Do]; (iii) [α|y.,mis, Do]; (iv) [γ, β, υ, Σ y.,mis|τ, Do]; and (v) [τ|υ].
We briefly discuss how to sample from each of the above conditional distributions as 
follows. For (i), the posterior distribution of θ conditional on Do is given by 
, which is log-concave in each component of θ. For 
(ii), the posterior distribution of λ conditional on Do is given by
Chen et al. Page 9






















which is also log-concave in each component of λ. For (iii), the conditional posterior 
distribution of α given y.,mis(0) and Do is of the form:
which is again log-concave. Thus, we can use the adaptive rejection algorithm of Gilks and 
Wild [27] to generate θ, λ, and α from the above three conditional distributions.
For (iv), we run a sub-Gibbs sampling algorithm to sample (γ, β, υ, Σ, ymis) from the joint 
conditional distribution. The conditional posterior distributions required by this sub-Gibbs 
sampling algorithm are given as follows:
(iva) [γ|β, υ, Σ, ymis, Do];
(ivb) [β|γ, υ, Σ, ymis, Do];
(ivc) [υ|γ, β, Σ, ymis, Do];
(ivd) [Σ|γ, β, υ, ymis, − K, Do), where ymis, − K denotes all missing treatment outcomes 
with exclusion of those (yik’s such that all (yi1,…, yiK) are missing and none of these K 
missing treatment outcomes are included in (3.7) and (3.8); and
(ive) [ymis|γ, β, υ, Σ, Do].
From these conditional distributions, we see that we have collapsed out most of the missing 
treatment outcomes yik’s in (iva), (ivb) and (ivc). This sub-Gibbs sampling algorithm is 
called the modified collapsed Gibbs sampler in Chen et al. [26]. In addition, the conditional 
posterior distributions of the components of γ, β, and υ are either univariate or multivariate 
normals, and the conditional posterior distributions of Σ1 and Σ2 are inverse Wisharts. Thus, 
sampling γ, β, υ, and Σ is straightforward. The conditional posterior distributions of the 
missing treatment outcomes in ymis are either normals or log-concave. Therefore, we sample 
those missing treatment outcomes either from the normals or using the adaptive rejection 
algorithm of Gilks and Wild [27]. Finally, we mention that for (v), τ follows an inverse 
gamma distribution and hence, sampling τ is straightforward.
5. Analysis of the Mild Cognitive Impairment Data
We present in this section the descriptive statistics and a detailed analysis of the data from 
the MCI trial discussed in Section 2. As shown in Table 1, of the 1011 enrolled patients, 505 
(50%) were assigned to Exelon treatment; 36 and 10 had intermittent missingness on the 
per- and off-protocol outcome measurements, respectively; 472 (46.7%) complied with the 
original assignment and stayed till the end of the study. For this particular dataset, we found 
that after the patients discontinued the assigned treatment, he/she either started the standard 
treatment and came back to the clinic right away, or never came back to the clinic (L = R). 
Using the notations defined in Section 3.1, Table 1 also provides the summary information 
for all the observed combinations of the per- and off-protocol schedule. For example, among 
the 28 patients stopping their assigned treatment at visit 2 and starting the standard treatment 
at the same time (R = S = 2), one completely withdrew from the study at visit 5 (L = 5), two 
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completely withdrew at visit 6 (L = 6), and 25 stayed till the end of the study (L = 7). 
Furthuremore, among those 28 patients, nobody had intermittent missing for per-protocol 
outcome (IM Y1 = 0); four had intermittent missing for off-protocol outcome (IM Y2 = 4); 12 
were assigned to Exelon treatment originally.
To implement the method proposed in Section 3 to MCI trial, we considered four covariates 
for xi in (3.2) and (3.1), where xi1 = the baseline composite z-score (CZSCR0), xi2 = age, xi3 
= sex (1 =female and 0 =male), and xi4 = EDUGRP (1 = High education group and 0 = 
otherwise). Thus, we have
for j = 1,2. Similarly, in (3.1) and (3.7), we took 
 and 
, where yi0 = CZSCROi. As 
shown in Table 1, there were only 10 ℓi values such that si < ℓi < K + 1, which essentially 
implies that there were only 9 “events" for the model (3.8). To ensure the model 
identifiability, we took a single covariate for Wi, namely, wi = EDUGRPi in (3.8). We also 
tried CZSCR0, age, or sex as wi and we found that EDUGRP was most related to Li. In all of 
the computations, we standardized age for numerical stability and centerized ti at 4, which 
corresponds to 24 months, for improving convergence of the Gibbs sampling algorithm.
The posterior means (Estimates), posterior standard deviations (SDs), and 95% highest 
posterior density (HPD) intervals of the model parameters are reported in Tables 2 to 4. 
Tables 2 to 4 as well as Tables A1 and A2 in the supplemental material reveal some very 
interesting results. When examining Table 4, in the case of both the models for per-protocol 
and off-protocol outcome measurements, it is clear that the drug shows no evidence of a 
positive treatment effect at any time point. Nevertheless, by examining the R, S and L 
models, it is possible to assess how covariates affect the pattern of withdrawal from study 
treatment and whether a patient is more likely to return to the clinic following withdrawal 
from the assigned study treatment.
In the case of the R model, patients in the Exelon group have a higher tendency to withdraw 
from the experimental treatment at the first visit (the 95% HPD interval for the log-odds 
excludes 0). As this effect seems not to be present in subsequent visits, this seems to reflect 
the problem of initial toleration. A further interesting relationship can be seen in subjects 
with high levels of education, who appear to be more likely to withdraw from study 
treatment, either Exelon or placebo, but only after at least 1 year. As there appears to be no 
evidence of a treatment effect in either of the education groups, it can be speculated that 
subjects with higher levels of education were more likely to be able to evaluate the treatment 
benefit and therefore withdraw from study treatment, if noticeable benefits were not 
achieved within a reasonable time frame.
Due to sparse data, the S and L models provide less insight into possible covariate 
relationships. In the case of the L model, higher education level seems to increase the 
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propensity to withdraw completely from the study. This is not surprising given that 
education level was a predictive covariate in the R model. In Table 3, we see evidence of 
nonignorable missing data in that the 95% HPD interval for yi,k−1 does not contain 0, 
indicating its significance. Again, for the L model, the 95% HPD interval for Visit does not 
contain 0, which indicates different dropout patterns over time. For the S model, we see 
from Table 3 that the 95% HPD interval for yi,ri−1 does not include zero, which implies that 
whether a patient starts the standard treatment after stopping the assigned treatment highly 
depends primarily on treatment outcome at the previous visit. When linking these results to 
Figure 2 in the supplemental file, which compares covariate relationships for the marginal L 
model between the treatment groups, we again see that the largest difference between 
Exelon and placebo is observed at the first visit in highly educated females.
To achieve the goodness-of-fit, we fit the largest identifiable models to the MCI data using 
all available covariates. For example, for the R model, we compared the proposed 
multivariate logistic regression model to a more parsimonious proportional odds regression 
model. Specifically, the values of AIC were 3158.52 for the proposed model and 3234.47 
for the proportional odds regression model. Similar results were obtained based on the 
deviance information criterion (DIC). We would like to mention that with the likelihood 
function and the posterior distribution developed in Sections 3 and 4, other Bayesian model 
comparison criteria such as the conditional predictive ordinate (CPO) and the Bayes factor 
can be used to evaluate the model fit. Due to the length of the paper, we have not included 
those comparisons in this paper. In addition, we compared the results under our proposed 
model to those obtained from the mixed effects models for the outcome measurements 
collected when the patients were on-protocol and when they were off-protocol, separately. 
Specifically, we consider the following models:
(5.1)
where the notations are the same as in Section 3. Table 4 provides the estimates, standard 
errors, and 95% confidence intervals (CIs) of the parameters under model (5.1). From Table 
4, we see that the estimates of the model parameters from the proposed model were slightly 
different than those from the standard mixed effects models particularly for the longitudinal 
process corresponding to the standard treatment. These modest differences are expected 
since the proposed model assumes that the drop-out (i.e., the L model) is nonignorable while 
the standard mixed effects models assume MAR for the missing outcomes from the standard 
treatment.
In all the Bayesian computations, we used 50,000 Gibbs samples after a burn-in of 2000 for 
each model, to compute all the posterior estimates, including posterior means, posterior 
standard deviations, and 95% HPD intervals. Codes were written for FORTRAN 95 
compiler, and we used IMSL subroutines with double precision accuracy. The convergence 
of the Gibbs sampler was checked using several diagnostic procedures as recommended by 
Cowles and Carlin [28]. The autocorrelations for all model parameters disappeared before 
lag 10. The HPD intervals were computed by the Monte Carlo method developed by Chen 
and Shao [29].
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We have proposed a novel class of models for accommodating two different types of 
longitudinal processes in studies where patients stop taking the assigned treatment and then 
start a standard treatment. We have developed a model that links these two longitudinal 
processes together through a multivariate linear mixed model. In order to account for the 
different types of dropout patterns, three types of missingness indicators (R, L, S) are 
incorporated into the modeling structure as described in detail in the paper. The model is 
sophisticated and complex and provides the user with an analysis tool in analyzing such 
longitudinal processes for which the only other alternative would be to do an analysis 
ignoring the standard treatment data. Due to a large percentage of missing values in both 
per- and off-protocol outcomes, sampling from the posterior distribution is extremely 
challenging. To overcome such difficulty, we have developed an efficient Gibbs sampling 
algorithm based on the modified collapsed Gibbs technique of [26] to sample from the 
posterior distribution under such a complex model.
As pointed out by one reviewer, s is a deterministic function of r and ℓ, namely, s = r if r ≠ ℓ 
and s = K + 1 if r = ℓ. The deterministic relationship between s and (r, ℓ) is in fact built in 
the proposed models for Si and Li in (3.7) and (3.8). This deterministic relationship leads to 
another view of our proposed model, in which we may model [Ri][Yi|Ri][Li|Ri, Yi] and ignore 
the model for Si. Under this alternative model, we need to model Li for ri ≤ Li ≤ K + 1 when 
ri < K + 1 instead of si + 1 ≤ Li < K + 1 when ri = si < K. The alternative model is equivalent 
to the proposed model if we assume
and then assume
It is easy to see that
A possible different model is to directly assume a multivariate logistic regression model for 
[Li|Ri = ri,yi] for ri ≤ Li ≤ K + 1. However, the standard saturated multivariate logistic 
regression model is not identifiable due to the sparsity of the subset of the observed data 
with ri < ℓi < K + 1. Thus, the proposed model is preferred and it can also allow for building 
in different non-ignorable missing patterns since both P(Li = ri|Ri = ri, yi) and P(Li = ℓi|Li > 
ri, Ri = ri, yi) may depend on missing values of yi. This is one reason why we chose to model 
Chen et al. Page 13






















[Ri][Yi|Ri][Si|Ri, Yi][Li|Si, Ri, Yi] rather than [Ri][Yi|Ri][Li|Ri, Yi]. Another reason is that the 
proposed model is easy to understand for practitioners since Si naturally follows after Ri and 
Li follows after Si.
Future work for the proposed model includes allowing for discrete responses or time-to-
event responses along with time-varying covariates. An additional area for future research 
could be based around developing an overall treatment effect summary based on an 
estimand that combines information from the per-protocol and off-protocol models. Work 
on an overall treatment effect estimate would be particularly important when planning a new 
clinical trial, as opposed to post-hoc exploratory analysis presented here. In the context of 
planning, the National Research Council report emphasizes the need for the clear 
identification of a target estimand (e.g. intention-to-treat estimand). The model developed in 
this paper contains separate treatment effect parameters associated with each study visit for 
both per-protocol and off-protocol data. However, in a drug development setting regulators 
would have to primarily base decision making on an overall treatment effect, possibly based 
on a weighted average of the per- and off-protocol models. These future research topics are 
under investigation currently.
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Appendix
A. The Predictive Distributions of R, S, and L
To characterize the patterns of treatment switching and dropout, it is of great clinical 
importance to derive the predictive distributions of R, S, and L. Let z* denote the treatment 
indicator, and x* and w* be vectors of covariates. The predictive distribution of R is straight 
forward and similar to (3.1). Conditioning on R, the predictive distribution of S is given as 
follows. For s < K + 1,
(A.
1)
and for s = K + 1,
(A.
2)
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where P(S = s|R = s, z*, x*, ys−1, λ) is defined in (3.7) and P(R = K + 1|z*, x*, x*, θ, γ, β, Σ, 
τ2) is denned in (3.1).
Similarly, the predictive distribution of L is given as follows. For ℓ < K + 1,
(A.
3)
and for ℓ = K + 1,
(A.
4)
where P(L = ℓ|R = k, S = k, t, w*, y, α) is defined in (3.8), P(R = K + l|z*, x*, θ, λ, γ, β, Σ, 
τ2) is denned in (3.1) P(S = K|z*, x*, α, θ, λ, γ, β, Σ, τ2) is denned in (A.2), f(y|R = k, z*, x*; 
γ, β, Σ, τ2) is given in (3.6).
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Selected On-/Off-protocol Patterns with Exampled Outcome Observations from Both 
Placebo (P) and Treatment (T) Groups (top) and boxplots of On- and Off-protocol Outcomes 
(bottom). For top panel, values were labeled as “NA”s if responses were missing 
intermittently and as “UO”s (unobserved) if patients completely withdrawed from study.
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Plots of the estimated predictive probabilities along with 95% HPD intervals of R, where 
three columns correspond to three quartiles (−4.738, 0.491, 5.024) of the baseline measure; 
and four rows correspond to male and low education group, male and high education group, 
female and low education group, and female and high education group.
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Table 2
Posterior estimates of the parameters for the R−model
Visit Variable Estimate SD 95% HPD Interval
1 Intercept −2.240 0.223 (−2.681, −1.812)
Treatment 1.042 0.205 ( 0.639, 1.443)
CZSCR0 −0.004 0.017 (−0.037, 0.028)
age 0.118 0.104 (−0.086, 0.323)
sex 0.732 0.202 ( 0.324, 1.116)
EDUGRP 0.224 0.240 (−0.253, 0.691)
2 Intercept −1.637 0.211 (−2.058, −1.230)
Treatment −0.027 0.224 (−0.461, 0.415)
CZSCR0 −0.072 0.018 (−0.108, −0.036)
age −0.054 0.119 (−0.288, 0.179)
sex 0.176 0.229 (−0.270, 0.630)
EDUGRP 0.067 0.289 (−0.502, 0.635)
3 Intercept −2.081 0.234 (−2.536, −1.623)
Treatment 0.034 0.228 (−0.422, 0.471)
CZSCR0 −0.100 0.019 (−0.137, −0.064)
age 0.164 0.124 (−0.071, 0.416)
sex 0.317 0.239 (−0.162, 0.776)
EDUGRP 0.856 0.272 ( 0.320, 1.379)
4 Intercept −2.271 0.268 (−2.802, −1.755)
Treatment 0.057 0.275 (−0.467, 0.610)
CZSCR0 −0.126 0.023 (−0.170, −0.082)
age −0.122 0.147 (−0.410, 0.167)
sex −0.337 0.290 (−0.897, 0.240)
EDUGRP 0.967 0.316 ( 0.354, 1.595)
5 Intercept −2.326 0.276 (−2.859, −1.775)
Treatment −0.064 0.283 (−0.617, 0.495)
CZSCR0 −0.106 0.023 (−0.151, −0.061)
age −0.054 0.151 (−0.354, 0.239)
sex 0.049 0.292 (−0.519, 0.627)
EDUGRP 0.686 0.336 ( 0.017, 1.334)
6 Intercept −2.485 0.275 (−3.011, −1.940)
Treatment 0.222 0.268 (−0.307, 0.743)
CZSCR0 −0.082 0.022 (−0.125, −0.039)
age 0.127 0.145 (−0.149, 0.417)
sex 0.258 0.278 (−0.282, 0.808)
EDUGRP 0.810 0.314 ( 0.184, 1.411)
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